Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis followed by Preemptive Approach versus Prophylaxis to Prevent CMV Infection in CMV-Seropositive Kidney Transplant Recipients Receiving Anti-thymocyte Globulin Induction Therapy
TCTR20240622001Phase 3Completed
- Sponsor
- Faculty of Medicine Ramathibodi Hospital, Mahidol University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in cytomegalovirus disease (CMV), sponsored by Faculty of Medicine Ramathibodi Hospital, Mahidol University. Started Jul 2024; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on TCTR20240622001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240622001.